公开(公告)号：US06576250B1

公开(公告)日：2003-06-10

申请号：US09664870

申请日：2000-09-19

申请人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz

发明人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz

IPC分类号： A61K902

CPC分类号： A61K9/006 ,  A61K9/0007 ,  A61K9/0056 ,  A61K9/2072 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/4468 ,  A61K31/5415

摘要： The pharmaceutical compositions of the present invention comprise rectally and vaginally administerable dosage forms that contain effervescent agents as penetration enhancers for drugs. Effervescence occurs in the rectum or vagina, once the dosage form is administered or at a predetermined time following administration. The effervescent agents can be used alone or in combination with pH adjusting substance, which further promote dissolution and absorption of the active ingredient.

摘要翻译： 本发明的药物组合物包含含有泡腾剂作为药物渗透促进剂的直肠和阴道给药剂型。 在直肠或阴道中发生泡腾，一旦施用剂型或在施用后的预定时间。 泡腾剂可以单独使用或与pH调节物质组合使用，这进一步促进活性成分的溶解和吸收。

公开(公告)号：US06764696B2

公开(公告)日：2004-07-20

申请号：US10346829

申请日：2003-03-18

申请人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

发明人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

IPC分类号： A61K924

CPC分类号： A61K9/2886 ,  A61K9/0007 ,  A61K9/2072 ,  A61K9/2866 ,  A61K9/5084 ,  Y10S514/96

摘要： The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.

摘要翻译： 本发明的药物组合物包含口服给药剂型，其使用泡腾作为已知或怀疑具有差的生物利用度的药物的渗透增强剂。 一旦片剂或其他剂型被摄取，起泡可能发生在胃中。 除了在胃中起泡或作为替代技术，通过使用适当的包衣和其它技术，泡腾可以发生在胃肠道的其它部分，包括但不限于食道，十二指肠和结肠。 选择泡腾和药物释放的部位以与显示配制药物的最大吸收的胃肠道的部分相对应，或获得一些其他治疗优势。

公开(公告)号：US06509036B2

公开(公告)日：2003-01-21

申请号：US10021486

申请日：2001-10-29

申请人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

发明人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

IPC分类号： A61K914

CPC分类号： A61K9/2886 ,  A61K9/0007 ,  A61K9/2072 ,  A61K9/2866 ,  A61K9/5084 ,  Y10S514/96

摘要： The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.

公开(公告)号：US6139874A

公开(公告)日：2000-10-31

申请号：US302105

申请日：1999-04-29

申请人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

发明人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

摘要： The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.

公开(公告)号：US08802130B2

公开(公告)日：2014-08-12

申请号：US11511098

申请日：2006-08-28

申请人： S. Indiran Pather ,  Rajendra K. Khankari ,  Jonathan D. Eichman ,  Joseph R. Robinson ,  John Hontz

发明人： S. Indiran Pather ,  Rajendra K. Khankari ,  Jonathan D. Eichman ,  Joseph R. Robinson ,  John Hontz

IPC分类号： A61F13/00

CPC分类号： A61K9/0007 ,  A61K9/0056 ,  A61K9/006 ,  A61K31/4468 ,  A61K31/5415

摘要： A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

摘要翻译： 一种药物剂型，其适于向口腔中提供药物的口腔，舌下或牙龈吸收，所述药物包含与可用于促进所述药物在口腔中的吸收的泡腾剂相结合的可口服给药的药物。 还公开了与泡腾剂结合使用另外的pH调节物质以促进吸收药物。

公开(公告)号：US06641838B2

公开(公告)日：2003-11-04

申请号：US10021109

申请日：2001-10-29

申请人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

发明人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

IPC分类号： A61K928

CPC分类号： A61K9/2886 ,  A61K9/0007 ,  A61K9/2072 ,  A61K9/2866 ,  A61K9/5084 ,  Y10S514/96

摘要： The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.

公开(公告)号：US06391335B1

公开(公告)日：2002-05-21

申请号：US09613270

申请日：2000-07-10

申请人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

发明人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

IPC分类号： A61K946

CPC分类号： A61K9/2886 ,  A61K9/0007 ,  A61K9/2072 ,  A61K9/2866 ,  A61K9/5084 ,  Y10S514/96

摘要： The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.

公开(公告)号：US06350470B1

公开(公告)日：2002-02-26

申请号：US09302105

申请日：1999-04-29

申请人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

发明人： S. Indiran Pather ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Rajendra K. Khankari ,  John Hontz ,  Sangeeta V. Gupte

IPC分类号： A61K924

CPC分类号： A61K9/2886 ,  A61K9/0007 ,  A61K9/2072 ,  A61K9/2866 ,  A61K9/5084 ,  Y10S514/96

摘要： The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.

摘要翻译： 本发明的药物组合物包含口服给药剂型，其使用泡腾作为已知或怀疑具有差的生物利用度的药物的渗透增强剂。 一旦片剂或其他剂型被摄取，起泡可能发生在胃中。 除了在胃中起泡或作为替代技术，通过使用适当的包衣和其它技术，泡腾可以发生在胃肠道的其它部分，包括但不限于食道，十二指肠和结肠。 选择泡腾和药物释放的部位以与显示配制药物的最大吸收的胃肠道的部分相对应，或获得一些其他治疗优势。

公开(公告)号：US06280770B1

公开(公告)日：2001-08-28

申请号：US09374393

申请日：1999-08-13

申请人： S. Indiran Pather ,  Sangeeta V. Gupte ,  Rajendra K. Khankari ,  John Hontz ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Ramya Kumbale

发明人： S. Indiran Pather ,  Sangeeta V. Gupte ,  Rajendra K. Khankari ,  John Hontz ,  Joseph R. Robinson ,  Jonathan D. Eichman ,  Ramya Kumbale

IPC分类号： A61K914

CPC分类号： A61K9/1075 ,  A61K9/0007 ,  A61K9/143 ,  Y10S514/937 ,  Y10S514/938

摘要： Novel pharmaceutical compositions which improve the rate and/or extent of absorption of drugs are disclosed. The novel pharmaceutical compositions of the present invention comprise drug-containing microemulsions adsorbed onto solid particles which may be further formulated into solid dosage forms. The compositions and dosage forms of the present invention improve the bioavailability of a wide range of drugs including drugs that are known or suspected of having poor bioavailability by the utilization of several different mechanisms.

摘要翻译： 公开了提高药物吸收速率和/或程度的新型药物组合物。 本发明的新型药物组合物包含吸附在固体颗粒上的含药微乳液，其可进一步配制成固体剂型。 本发明的组合物和剂型通过利用几种不同的机制来改善广泛范围的药物的生物利用度，包括已知或怀疑具有差的生物利用度的药物。

公开(公告)号：US06200604B1

公开(公告)日：2001-03-13

申请号：US09327814

申请日：1999-06-08

申请人： Sathasivan Indiran Pather ,  Rajendra K. Khankari ,  Jonathan D. Eichman ,  Joseph R. Robinson ,  John Hontz

发明人： Sathasivan Indiran Pather ,  Rajendra K. Khankari ,  Jonathan D. Eichman ,  Joseph R. Robinson ,  John Hontz

IPC分类号： A61K946

CPC分类号： A61K31/5415 ,  A61K9/0007 ,  A61K9/0056 ,  A61K9/006 ,  A61K31/4468

摘要： A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

摘要翻译： 一种药物剂型，其适于向口腔中提供药物的颊，舌下或牙龈吸收，所述药物包含与用于促进药物在口腔中吸收的口腔可药用组合泡腾剂。 还公开了与泡腾剂结合使用另外的pH调节物质以促进吸收药物。